Brought to you by 
Sandoz buys for rest of SyStemix for $75.6mm
13 Jul 1999
Executive Summary
Sandoz made an unsolicited bid for the 27% of SyStemix (stem cell-based gene therapy) it doesn't already own, offering $17 per share, a 55% premium to its pre-offer price.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sandoz buys for rest of SyStemix for $75.6mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice